| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 250mg |
|
| ln Vitro |
In the plasma membrane of LM cells (transformed fibroblasts), prilocaine hydrochloride inhibits Na,K-ATPase more effectively at 37 °C (43.8 mM) than at 25 °C (28.2 mM) [2].
|
|---|---|
| References | |
| Additional Infomation |
Prilocaine Hydrochloride is the hydrochloride salt form of prilocaine, an intermediate-acting local anesthetic of the amide type chemically related to lidocaine. Prilocaine hydrochloride binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions. This leads to a stabilization of the neuronal membrane and inhibits depolarization and results in a reversible blockage of nerve impulse generation and propagation along nerve fibres and subsequent reversible loss of sensation.
A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry. See also: Prilocaine (has active moiety); Epinephrine Bitartrate; prilocaine hydrochloride (component of). |
| Molecular Formula |
C13H21CLN2O
|
|---|---|
| Molecular Weight |
256.77
|
| Exact Mass |
256.134
|
| CAS # |
1786-81-8
|
| Related CAS # |
Prilocaine;721-50-6;Prilocaine-d7 hydrochloride;Prilocaine acetate
|
| PubChem CID |
92163
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
85°C 4mm
|
| Melting Point |
168-170ºC
|
| Flash Point |
134.3ºC
|
| Vapour Pressure |
2.05E-05mmHg at 25°C
|
| LogP |
3.587
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
218
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O=C(C([H])(C([H])([H])[H])N([H])C([H])([H])C([H])([H])C([H])([H])[H])N([H])C1=C([H])C([H])=C([H])C([H])=C1C([H])([H])[H]
|
| InChi Key |
BJPJNTKRKALCPP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H20N2O.ClH/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)1H
|
| Chemical Name |
N-(2-methylphenyl)-2-(propylamino)propanamidehydrochloride
|
| Synonyms |
Prilocaine HydrochloridePropitocaine hydrochloridePrilocaine HClXylonestCitanest OctapressinPrilocaine chlorideXylonest
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8945 mL | 19.4727 mL | 38.9454 mL | |
| 5 mM | 0.7789 mL | 3.8945 mL | 7.7891 mL | |
| 10 mM | 0.3895 mL | 1.9473 mL | 3.8945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05877690 | Recruiting | Drug: Prilocaine Hydrochloride 2% Injection |
Hemodynamic Stability | Assiut University | October 2023 | Not Applicable |
| NCT01412632 | Completed | Drug: Remifentanil, propofol and citanest |
Transcervical Resection of Endometrium Transcervical Resection of Fibroids |
University of Aarhus | November 2011 | Phase 4 |
| NCT05668286 | Recruiting | Drug: A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) |
Adhesive Capsulitis of the Shoulder | Kartal City Hospital | May 24, 2024 | Not Applicable |
| NCT04161586 | Completed | Drug: Prilocaine Hydrochloride | Anesthesia, Spinal Prilocaine |
Ospedale di Circolo - Fondazione Macchi |
January 1, 2011 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
